Prostate Cancer News and Research

Latest Prostate Cancer News and Research

LCA comments on CDC's new anti-tobacco campaign

Today, Lung Cancer Alliance (LCA) said that the new anti-tobacco campaign just launched by the Centers for Disease Control and Prevention (CDC) is an important revitalization of the efforts to prevent young people from smoking and encourage all who do smoke to quit.

17 Mar 2012

Guidelines for cervical cancer screening revised

The guidelines say that women between 30 and 65 can wait five years between screenings if they get both a Pap test and an HPV test.

16 Mar 2012

NEJM publishes results from Teva's laquinimod Phase III study on RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the publication of results from the laquinimod Phase III ALLEGRO study in the March 15 issue of The New England Journal of Medicine.

16 Mar 2012

Prostate cancer screening debate continues

Routine tests that help detect prostate cancer actually do reduce the risk of death from the disease, researchers said. Screening is done with a simple blood test that measures levels of prostate-specific antigen, or PSA.

15 Mar 2012

MDxHealth fourth quarter total revenues increase 48% to €0.9M

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced results for Q4 and full year 2011.

15 Mar 2012

African Americans in Georgia found to have poor survival rates from cancer

African Americans in Georgia, especially in rural areas, have drastically poorer survival rates from cancer. These disparities are much larger when compared to national data, according to the findings from a study recently published in the journal Cancer by a team of researchers in the University of Georgia College of Public Health.

14 Mar 2012

Modified Citrus Pectin binds and blocks harmful effects of Galectin-3

Galectin-3 sounds like a planet out of "Star Trek," but it can be much more ominous. Recently, distinguished integrative physician Isaac Eliaz, M.D., presented breakthrough research demonstrating that the protein Galectin-3 is an active biomarker for numerous life-threatening diseases. Even more importantly, Dr. Eliaz showed how Modified Citrus Pectin (MCP) binds and blocks Galectin-3 throughout the body.

14 Mar 2012

Scientists track genetic pathway of prostate cancer in new approach to drug discovery

Tracking the genetic pathway of a disease offers a powerful, new approach to drug discovery, according to scientists at the University of California, San Diego School of Medicine who used the approach to uncover a potential treatment for prostate cancer, using a drug currently marketed for congestive heart failure. Their findings are published in the current online issue of the Proceedings of the National Academy of Sciences.

14 Mar 2012

Researchers crack problem of predicting gene targets for PcG proteins

Cancer is usually attributed to faulty genes, but growing evidence from the field of cancer epigenetics indicates a key role for the gene "silencing" proteins that stably turn genes off inside the cell nucleus. A new study from Rice University and Baylor College of Medicine promises to speed research in the field by rapidly identifying the genes that epigenetic proteins can target for silencing.

14 Mar 2012

Scotland says no to prostate cancer drug Abiraterone

Patients with advanced prostate cancer in Scotland will not get access to a new drug which can extend their lives by more than three months. Prostate cancer is the most common cancer to affect men and the second most common cause of death.

13 Mar 2012

Cancer Research UK disappointed over SMC ruling against advanced prostate cancer drug

Cancer Research UK is extremely disappointed that the advanced prostate cancer drug, abiraterone, has been ruled too expensive for routine use by the Scottish Medicines Consortium (SMC).

12 Mar 2012

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of multi-organ failure (MOF), announced today that the Company has initiated a 200-patient Phase 2 pilot study to examine the efficacy and safety of InflammaGen Shok-Pak as a potential treatment for critically ill patients in the Intensive Care Unit.

12 Mar 2012

Circumcision may decrease risk of prostate cancer

A new analysis led by researchers at Fred Hutchinson Cancer Research Center has found that circumcision before a male's first sexual intercourse may help protect against prostate cancer. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study suggests that circumcision can hinder infection and inflammation that may lead to this malignancy.

12 Mar 2012

Cancer rates to fall among men but slightly rise among women by 2020: Report

The report says that due to the growing and ageing population the actual number of new cases will rise by almost 40 per cent on 2007 levels. But when that's converted to the number of cases per 100,000 people the results are surprising. Cancer rates in men will fall from 595 to 568 cases per 100,000 by 2020. That equates to about 85,000 cases. When it comes to women the rate is projected to rise from 394 to 408 cases per 100,000. That's equivalent to 65,000 new cases in 2020.

11 Mar 2012

Obesity, medical distrust contribute to high rates of prostate cancer in Louisiana

Factors such as increased risk for African-Americans, obesity and medical distrust contribute to high rates of prostate cancer in Louisiana. Louisiana has the fourth highest prostate cancer death rate in the country and the sixth highest incidence rate, according to data from North American Association of Central Cancer Registries, National Cancer Institute and the Centers for Disease Control and Prevention.

9 Mar 2012

Elekta Clarity 3D system transforms prostate radiotherapy at UHG

Soft tissue imaging with 3D ultrasound both at therapy simulation and just before treatment has transformed prostate radiotherapy at University Hospital Galway.

From Elekta 9 Mar 2012

DC has highest prostate cancer incidence and death rate

Increased risk for African-Americans, medical distrust and negative attitudes toward testing contribute to high rates of prostate cancer in the District of Columbia. DC has the highest prostate cancer incidence rate and death rate in the country, according to data from North American Association of Central Cancer Registries, National Cancer Institute and the Centers for Disease Control and Prevention.

9 Mar 2012

Bellicum raises $20M in Series B financing

Bellicum Pharmaceuticals, Inc. today announced that it has raised $20 million in a Series B financing. The funding will be used to advance its lead CaspaCIDe and DeCIDe programs through Phase 2 clinical development.

8 Mar 2012

Combining radiation therapy with ipilimumab shows promise against melanoma

Research published today in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer.

8 Mar 2012

Exelixis initiates cabozantinib and abiraterone phase 1 combination trial in CRPC

Exelixis Inc. today announced the initiation of a phase 1 dose-finding trial of cabozantinib in combination with abiraterone in men with metastatic castration-resistant prostate cancer (CRPC) who have disease progression following treatment with up to two prior chemotherapy regimens.

5 Mar 2012